Disitamab Vedotin (RC48-ADC) in Breast Cancer | NCT05851677 | Trialant

Disitamab Vedotin (RC48-ADC) in Breast Cancer | NCT05851677 | Trialant

Arms/Interventions Module

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Progression-Free Survival	The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.	From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)

Secondary Outcomes

Measure	Description	Time Frame
Adverse events	Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0.	From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)

Contacts/Locations Module

Condition Browse Module